Cell death can be induced by genetic intervention in a variety of ways
. We review genetic prodrug activation therapies using both mammalian
and non-mammalian enzyme systems as well as the expression of toxin ge
nes and apoptotic triggers. Targeting of the genetic intervention usin
g both transductional restriction and transcriptional control elements
is examined in both in vitro and in vivo systems, and the present sta
te of clinical trials is reviewed.